Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IDYA 
Ideaya Biosciences Inc (IDYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IDYA (3-star) is a STRONG-BUY. BUY since 116 days. Simulated Profits (38.64%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $47.06
1 Year Target Price $47.06
| 10 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 111.05% | Avg. Invested days 59 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.37B USD | Price to earnings Ratio - | 1Y Target Price 47.06 |
Price to earnings Ratio - | 1Y Target Price 47.06 | ||
Volume (30-day avg) 13 | Beta 0.14 | 52 Weeks Range 13.45 - 32.67 | Updated Date 10/14/2025 |
52 Weeks Range 13.45 - 32.67 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5488.94% |
Management Effectiveness
Return on Assets (TTM) -23.84% | Return on Equity (TTM) -35.09% |
Valuation
Trailing PE - | Forward PE 4.65 | Enterprise Value 1740767259 | Price to Sales(TTM) 338.93 |
Enterprise Value 1740767259 | Price to Sales(TTM) 338.93 | ||
Enterprise Value to Revenue 248.68 | Enterprise Value to EBITDA -7.8 | Shares Outstanding 87643686 | Shares Floating 81816257 |
Shares Outstanding 87643686 | Shares Floating 81816257 | ||
Percent Insiders 0.91 | Percent Institutions 119.84 |
Upturn AI SWOT
Ideaya Biosciences Inc
Company Overview
History and Background
Ideaya Biosciences, Inc. is a precision medicine oncology company committed to the discovery and development of targeted therapeutics. Founded in 2011, Ideaya has focused on synthetic lethality and other precision medicine approaches to identify and develop innovative cancer treatments.
Core Business Areas
- Synthetic Lethality: Ideaya focuses on discovering and developing drugs that exploit synthetic lethality, where the inhibition of two genes leads to cell death, while inhibiting only one does not.
- Precision Medicine Oncology: The company targets genetically defined patient populations with specific mutations or biomarkers that are more likely to respond to their therapies.
- Drug Discovery and Development: Ideaya conducts research and development activities to identify, validate, and advance novel drug candidates through preclinical and clinical stages.
Leadership and Structure
The leadership team includes Yujiro S. Hata, Chief Executive Officer, and Gregory P. Mayes, Chief Financial Officer. The company operates with a focus on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- IDE196: A protein kinase C (PKC) inhibitor targeting cancers with genetic mutations. Currently in clinical development. There is no available market share data. Competitors: Other PKC inhibitors or therapies targeting the same genetic mutations.
- DARO-MET: A combination therapy that targets the metabolism of tumors and helps to inhibit the growth of cancerous cells. There is no available market share data. Competitors: Other therapies targeting metabolic alterations in cancer.
- IDE397: An MAT2A inhibitor targeting MTAP-deleted cancers, currently in clinical trials. There is no available market share data. Competitors: Other MAT2A inhibitors.
Market Dynamics
Industry Overview
The oncology drug market is large and rapidly growing, driven by increasing cancer incidence, advances in genomics, and the development of targeted therapies and immunotherapies. Precision medicine approaches are gaining prominence.
Positioning
Ideaya is positioned as a precision medicine company focusing on synthetic lethality and targeted therapies. Its competitive advantages include a pipeline of novel drug candidates and expertise in specific cancer pathways.
Total Addressable Market (TAM)
The oncology drug market is expected to reach hundreds of billions of dollars. Ideaya is positioned to capture a portion of this TAM through its targeted therapies for specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Novel drug discovery platform
- Strong focus on precision medicine
- Experienced leadership team
- Partnerships with leading pharmaceutical companies
- Pipeline of promising drug candidates
Weaknesses
- Dependence on clinical trial success
- High cash burn rate
- Competition from larger pharmaceutical companies
- Limited commercialization experience
- Relatively small market capitalization
Opportunities
- Advancement of drug candidates through clinical trials
- Expansion of pipeline through internal discovery and collaborations
- Potential for strategic partnerships and acquisitions
- Growing demand for precision medicine approaches
- Favorable regulatory environment for drug development
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Patent expirations
- Economic downturn
Competitors and Market Share
Key Competitors
- MRTX
- GILD
- BMY
- LLY
- AZN
- NVS
- PFE
- REGN
Competitive Landscape
Ideaya is a smaller player compared to larger pharmaceutical companies. Its advantages lie in its focus on precision medicine and synthetic lethality. However, it faces competition from established companies with greater resources and commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on the company's stage, refer to most recent filings for accurate numerical data.
Future Projections: Future projects are dependent on market performance, refer to most recent filings for accurate numerical data.
Recent Initiatives: Recent initiatives include the advancement of clinical trials, expansion of the drug pipeline, and strategic partnerships.
Summary
Ideaya Biosciences is a precision medicine company with a promising pipeline, but significant clinical and financial risks exist. Its focus on synthetic lethality is a strength, but successful clinical trials and strategic partnerships are crucial. Competition is high and commercialization remains a challenge. Securing funding is vital to support operations and to see pipeline potential to fruition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Company website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ideaya Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-23 | Founder, President, CEO & Director Mr. Yujiro S. Hata | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.ideayabio.com |
Full time employees 131 | Website https://www.ideayabio.com | ||
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.